News for Xenon Pharmaceuticals Inc. (XENE)

Xenon Pharmaceuticals (XENE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Summary Xenon Pharmaceuticals Inc (XENE), a leading neuroscience-focused biopharmaceutical company, announced on June 3, 2025, that it will be presenting at the

Summary Xenon Pharmaceuticals Inc (XENE), a biopharmaceutical company focused on neuroscience, announced on May 30, 2025, the issuance of equity inducement gran

**media[641753]**

Trump unveils vision for $175B ‘Golden Dome’ missile defense. Ford to let Nissan use its EV battery plant in Kentucky - report. Wolfspeed craters following potential bankruptcy: report.

On May 14, 2025, Evercore ISI Group announced the initiation of coverage on Xenon Pharmaceuticals (XENE) with an "Outperform" rating. This marks a significant d

We recently published an article titled Massive Sell-Offs Just Hit These 10 Stocks Today. In this article, we are going to take a look at where Xenon Pharmaceuticals Inc. (NASDAQ:XENE) stands against the other stocks. Wall Street’s main indices finished mixed on Tuesday, as investors digested the country’s latest inflation figures, which came out lower than […]

On May 13, 2025, renowned analyst Mohit Bansal from Wells Fargo provided an update on Xenon Pharmaceuticals (XENE). The pharmaceutical company's stock rating re

On May 13, 2025, RBC Capital maintained its "Outperform" rating for Xenon Pharmaceuticals (XENE), while lowering its price target. The updated price target for

U.S. stocks traded mixed midway through trading, with the Dow Jones index falling around 200 points on Tuesday. The Dow traded down 0.49% to 42,203.63 while th...

Revenue: $7.5 million recognized during the first quarter from a milestone payment related to a collaboration with Neurorene.Cash and Cash Equivalents: $691.1

May 12, 2025 / 08:30PM GMTOperator Thank you for standing by. My name is Carly, and I will be your conference operator today. At this time, I would like to welc

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Q1 2025 Earnings Conference Call May 12, 2025 4:30 AM ETCorporate ParticipantsChad Fugere - Vice President,...

”“ Phase 3 azetukalner X-TOLE2 FOS study patient recruitment expected to complete in the next few months with topline data anticipated in early 2026 ”“ Phase

Xenon (XENE) is making notable strides in its Phase 3 epilepsy initiative, with the X-TOLE2 study nearing completion of patient recruitment. This progress puts

Revenue: Achieved $7.5 million for Q1 2025, surpassing the estimated $1.11 million, driven by a milestone payment from the Neurocrine collaboration.Earnings Pe

Xenon Pharmaceuticals Inc (XENE) is set to release its Q1 2025 earnings on May 12, 2025. The consensus estimate for Q1 2025 revenue is $1.11 million, and the ea

On May 7, 2025, Chardan Capital has initiated coverage on Xenon Pharmaceuticals (XENE) with a "Buy" rating. The analyst behind this coverage is Rudy Li, who has

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiat...